The ProFoundry Platform has uncovered tens of thousands of novel proteins, remapping the landscape of the human genome and expanding the number of potential therapeutic targets, according to Flagship Pioneering. The company said the funding will be used toward supporting target discovery efforts and building a robust R&D pipeline.

The ProFoundry Atlas, a database that catalogs tens of thousands of novel proteins and their functionality, connectivity, and roles in health and disease, is at the core of the ProFoundry Platform.

"ProFound is systematically decoding this expanded proteome to understand how these proteins govern biology and enable the development of novel therapeutics across the spectrum of human diseases," said Avak Kahvejian, PhD, Flagship Pioneering general partner and co-founder and CEO of ProFound Therapeutics.

Flagship Pioneering unveils Vesalius Therapeutics
Flagship Pioneering unveiled Vesalius Therapeutics with an initial commitment of $75 million to support the development of Vesalius' platform and initial...

Laronde secures $440M for its Endless RNA platform
Laronde has secured $440 million in series B funding that it plans to use to further develop its Endless RNA platform.

Ring Therapeutics nabs $117M for vector platform for gene therapy
Ring Therapeutics has raised $117 million to support the continued development and expansion of its novel vector Anellogy platform.

Flagship Pioneering unveils eRNA platform from Laronde
Flagship Pioneering unveiled its Laronde platform for the development of endless RNA (eRNA), a novel, engineered form of RNA that can be programmed to...